An interventional study of intermittent theta burst stimulation and Sham stimulation in Major Depressive Disorder and Alcohol Use Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2024-03-08.
Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health — 10 open to participants now, 13 under way, none of them phase 3. Depressive Disorder, Major · Centre for Addiction and Mental Health.
Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, this one is the 32nd largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 36 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 41st registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →10 of the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–50
Centre for Addiction and Mental Health · Sites in Canada
Ages 60+ · Healthy volunteers
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–75 · Healthy volunteers
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 4 1
First in 2001; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 72 across the 44 interventional studies, 75 across the 4 observational. Of the 34 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
4 of the studies in Depressive Disorder, Major by Centre for Addiction and Mental Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04972136Centre for Addiction and Mental HealthrTMS for Depression in Young Adults With Autism | 2027-01-14 |
| NCT05583747Centre for Addiction and Mental HealthE-field Guided iTBS for Treatment Resistant Depression | 2027-03-31 |
| NCT04935619Centre for Addiction and Mental HealthExtended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression | 2027-06-30 |
| NCT05142683Centre for Addiction and Mental HealthEffectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD). Depressive symptoms are also highly prevalent in individuals with AUD. A number of cognitive and psychological processes stemming from the prefrontal cortex, a common treatment target for repetitive transcranial magnetic stimulation (rTMS), are disrupted in both MDD and AUD. The proposed study will enhance the development of theta burst stimulation (TBS) as a new intervention for AUD in the context of depressive symptoms and uses integrated TMS-EEG to identify neurophysiological targets of executive dysfunction in this disorder.
The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD). Depressive symptoms are also highly prevalent in individuals with AUD. A number of cognitive and psychological processes stemming from the prefrontal cortex, a common treatment target for repetitive transcranial magnetic stimulation (rTMS), are disrupted in both MDD and AUD. The proposed study will enhance the development of theta burst stimulation (TBS) as a new intervention for AUD in the context of depressive symptoms and uses integrated TMS-EEG to identify neurophysiological targets of executive dysfunction in this disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilteral TBS, applied as cTBS over the right DLPFC followed by iTBS over the left DLPFC
Device: intermittent theta burst stimulation
Sham TBS
Device: Sham stimulation
Theta-burst stimulation
Stimulation with double-sided B70-type coil
Executive Function Index - inhibition
Flanker task
Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)
Executive Function Index - working memory
N-back task
Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)
Executive Function Index - set shifting
switch task
Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)
17-Item Hamilton Depression Rating Scale (HRSD-17)
Decrease in 17-Item Hamilton Depression Rating Scale score, 0 is lowest value, 52 is highest, higher value = more severe depression
Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)
Columbia-Suicide Severity Rating Scale
Decrease in Columbia-Suicide Severity Rating Scale score, 0 is lowest score, 25 is highest, higher value = more suicidal ideation
Time frame: baseline and 4 weeks after baseline (after 20 treatments of active/sham rTMS)
Started Feb 2022 (actual). Primary completion is estimated for Dec 2024, 34 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 34 months is close to that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre for Addiction and Mental Health →